Evidence mapPaperPMID 40197856Full record

ArticlePharmacoepidemiology and drug safety2025

Discontinuation Categories Underlying Gaps in Dispensing for Six Medication Groups.

Elizabeth A Bayliss, Glenn K Goodrich, Jennifer C Barrow, Bill Harding, Courtney A Ripley, Courtney R Kraus, Valerie Paolino, Jonathan D Norton, Orla C Sheehan, Linda A Weffald and 5 more

Abstract read
In one paragraph

Article in Pharmacoepidemiology and drug safety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Elizabeth A BaylissInstitute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado, USA.ORCID https://orcid.org/0000-0002-5264-0670
Glenn K GoodrichInstitute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado, USA.
Jennifer C BarrowInstitute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado, USA.
Bill HardingInstitute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado, USA.
Courtney A RipleyInstitute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado, USA.
Courtney R KrausInstitute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado, USA.
Valerie PaolinoInstitute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado, USA.
Jonathan D NortonDivision of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Orla C SheehanDivision of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Linda A WeffaldDepartment of Clinical Pharmacy, Kaiser Permanente Colorado, Aurora, Colorado, USA.
Ariel R GreenDivision of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Ted E PalenInstitute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado, USA.
Emily ReeveQuality Use of Medicines and Pharmacy Research Centre, School of Pharmacy and Medical Science, University of South Australia, Adelaide, South Australia, Australia.
Matthew L MaciejewskiCenter of Innovation to Accelerate Discovery & Practice Transformation, Durham VA Medical Center, Durham, North Carolina, USA.
Cynthia M BoydDivision of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Funding

The U.S. Deprescribing Research NetworkR33AG086944 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI CYNTHIA Melinda BOYD, MICHAEL A. STEINMAN · 2024 to 2026
$2.5M
Generating Evidence on Deprescribing SafetyRF1AG070047 · NIA · KAISER FOUNDATION RESEARCH INSTITUTE · PI BAYLISS, ELIZABETH A, BOYD, CYNTHIA MELINDA · 2021 to 2021
$1.9M
Generating Evidence on Deprescribing SafetyR01AG070047 · NIA · KAISER FOUNDATION RESEARCH INSTITUTE · PI BAYLISS, ELIZABETH A, BOYD, CYNTHIA MELINDA · 2024 to 2024
$542k
HSRD VA IK6 HX003157NIA NIH HHS R01 AG070047NIA NIH HHS R33 AG086944NIA NIH HHS RF1 AG070047
6 · The paper itself

Abstract

purposeAccurately identifying medication discontinuations at scale is important for developing evidence about deprescribing. Gaps in dispensing often serve as proxies for discontinuation but are imprecise. We categorize reasons for gaps in dispensing to inform data-based methods to accurately identify medication discontinuations.

methodsUsing pharmacy dispensing data, we purposively sampled from a population of adults age 65+ with 2+ chronic conditions who experienced a 90-day gap in dispensing-with and without subsequent fills-of oral diabetes drugs, statins, proton pump inhibitors, drugs with anticholinergic properties, anticoagulants and antiplatelet drugs, or antihypertensives. We reviewed clinical documentation (e.g., visit notes, communications, medication orders) from last dispensing through the 90-day gap plus 120 days to classify dispensing gaps as true discontinuations (clinically intended) or non-discontinuations (no evidence of intent to discontinue), and then into subcategories. Medications with no documented explanation for the gap in dispensing and continued listing on the patient's medication list were classified as non-discontinuations.

resultsOf N = 1906 records reviewed, there were 1068 (56%) true discontinuations and 838 (44%) non-discontinuations. Subcategories within true discontinuations included provider intent to discontinue, provider substitutions, intentional stops followed by restarts, and agreeing with a colleague's or patient's decision to discontinue. Non-discontinuations included documented low adherence, changes in dose, changes in pharmacy formulary, and changes in drug formulation. Proportions of drugs in categories and subcategories varied by medication group.

conclusionUsing gaps in dispensing as proxy measures for medication discontinuation may introduce bias through misclassification, and varied reasons for discontinuation may complicate causal interpretations.

Indexed as

DeprescriptionsAgedAged, 80 and overFemaleHumansMaledeprescribingmedication discontinuationnatural language processingpharmacoepidemiologypragmatic trials

Identifiers

PMID40197856
PMCPMC12380114

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.